Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer

被引:7
作者
Jansman, FGA
Idzinga, FSF
Smit, WM
de Graaf, JC
Coenen, JLLM
Sleijfer, DT
Brouwers, JRBJ
机构
[1] Univ Groningen, Inst Drug Explorat, Dept Social Pharm Pharmacoepidemiol & Pharmacothe, NL-9713 AV Groningen, Netherlands
[2] Isala Klin, Dept Clin Pharm, Zwolle, Netherlands
[3] Med Spectrum Twente, Dept Med Oncol, Enschede, Netherlands
[4] Isala Klin, Dept Med Oncol, Zwolle, Netherlands
[5] Univ Groningen Hosp, Dept Med Oncol, Groningen, Netherlands
关键词
colorectal neoplasms; chemotherapy; drug interactions; adverse effects; irinotecan; oxaliplatin; epidemiology;
D O I
10.1016/j.clinthera.2005.03.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Pharmacokinetic and pharmacodynamic drug interactions with cytotoxic drugs may significantly influence the efficacy and toxicity of chemotherapy. Objective: The purpose of this study was to identify drug interactions with irinotecan and oxaliplatin reported in the literature, to assess their clinical significance, and to examine the occurrence of these interactions in patients with metastatic colorectal cancer treated with either irinotecan or oxaliplatin or both. Methods: To obtain data on drug-drug interactions with irinotecan and oxaliplatin, a literature search of PubMed and EMBASE was conducted using the search terms irinotecan, oxaliplatin, and interactions (English-language studies only published between 1980 and August 2004). The interactions found were subsequently classified for documentation evidence and severity of clinical effect, according to a 5-level classification system of a standard reference text, by a study panel of medical oncologists and clinical pharmacists. Comedication of patients who were treated with irinotecan or oxaliplatin, or both, was then examined to determine the occurrence of clinically significant interactions. Results: Ninety-eight patients (50 women, 48 men; mean age, 60 years) were included in the study. Seventeen interactions with irinotecan were found in the literature, and 11 were classified as clinically significant. Only 1 nonspecific, clinically significant interaction was identified for oxaliplatin. Irinotecan-treated patients received a mean of 8 different comedications and oxaliplatin-treated patients received a mean of 6. Apart from antiemetic and antidiarrheal drugs that were prescribed for treatment-related toxicities, only 1 patient appeared to be exposed to a possible clinically significant interaction (between irinotecan and phenytoin). Conclusions: Eleven of the 17 interactions with irinotecan that were found in the literature were classified as clinically significant versus 1 clinically significant interaction with oxaliplatin. The occurrence of these interactions in the study patients with metastatic colorectal cancer was low. For medication surveillance purposes, however, the significant interactions should be considered in clinical practice. Copyright (c) 2005 Excerpta Medica, Inc.
引用
收藏
页码:327 / 335
页数:9
相关论文
共 44 条
[1]   New approaches to prevent intestinal toxicity of irinotecan-based regimens [J].
Alimonti, A ;
Gelibter, A ;
Pavese, I ;
Satta, F ;
Cognetti, F ;
Ferretti, G ;
Rasio, D ;
Vecchione, A ;
Di Palma, M .
CANCER TREATMENT REVIEWS, 2004, 30 (06) :555-562
[2]   Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer [J].
Alimonti, A ;
Satta, F ;
Pavese, I ;
Burattini, E ;
Zoffoli, V ;
Vecchione, A .
ANNALS OF ONCOLOGY, 2003, 14 (05) :805-806
[3]  
[Anonymous], GUID ATC CLASS DDD A
[4]  
*AV PHARM BV, 2003, CAMPT PROD INF
[5]   Drug interactions in oncology [J].
Beijnen, JH ;
Schellens, JHM .
LANCET ONCOLOGY, 2004, 5 (08) :489-496
[6]   New systemic frontline treatment for metastatic colorectal carcinoma [J].
Braun, AH ;
Achterrath, W ;
Wilke, H ;
Vanhoefer, U ;
Harstrick, A ;
Preusser, P .
CANCER, 2004, 100 (08) :1558-1577
[7]   Estimates of cancer incidence and mortality in Europe in 1995 [J].
Bray, F ;
Sankila, R ;
Ferlay, J ;
Parkin, DM .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (01) :99-166
[8]  
*BRIST MYERS SQUIB, 2004, REYAT PROD INF
[9]   Oxaliplatin - A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies [J].
Culy, CR ;
Clemett, D ;
Wiseman, LR .
DRUGS, 2000, 60 (04) :895-924
[10]  
*EMEA CPMP, 1997, NOT GUID INV DRUG IN